Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406716 | 0.79 | TSHR (0.60) | TSHRLTA4HALDH1A1KCNH2 | |
| SCHEMBL12850076 | 0.78 | TSHR (0.49) | TSHRLTA4HALDH1A1 | |
| SCHEMBL863049 | 0.78 | TAAR1 (0.50) | LTA4HALDH1A1KCNH2 | |
| SCHEMBL6560986 | 0.76 | LTA4H (0.59) | LTA4HALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29562382 | 0.76 | LTA4H (0.59) | LTA4HALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3374720 | 0.76 | LTA4H (0.59) | LTA4HALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15294291 | 0.76 | LTA4H (0.59) | LTA4HALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL19715501 | 0.76 | TSHR (0.61) | TSHRALDH1A1 | |
| SCHEMBL26618251 | 0.75 | KCNH2 (0.59) | TSHRLTA4HKCNH2CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL19715538 | 0.75 | TSHR (0.59) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | TSHR 4108/4885LTA4H 772/4885ALDH1A1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.